

## Article Review: Production and Purification of Antibiotics from Environmental Microorganism

Saba Talab Hashim<sup>1</sup>, Saba Riad Khudhaier Al-Taei<sup>2</sup>, Tahreer Hadi Saleh<sup>3</sup> and Bahaa Abdullah Laftaah Al-Rubaii<sup>4</sup>

<sup>1,2,3</sup>Department of Biology, College of Science, Mustansiriyah University, Baghdad, IRAQ.

<sup>4</sup>Department of Biology, College of Science, University of Baghdad, Baghdad, IRAQ.

<sup>4</sup>Corresponding Author: bahaa974@gmail.com



[www.sjmars.com](http://www.sjmars.com) || Vol. 3 No. 4 (2024): August Issue

Date of Submission: 25-07-2024

Date of Acceptance: 29-07-2024

Date of Publication: 13-08-2024

### ABSTRACT

The use for antibiotics to treat microbial with bacteria has been for decades a mainstay of contemporary therapy. Nevertheless, extensive antimicrobial abuse or trafficking has resulted in unforeseen effects that need significant policy reforms for prevention. Researchers discuss two major categories of implications of antimicrobial misuse and excess use in this review. Subsequently talk about how antibiotic resistance spreads from hotspot where resistance evolution occurs to the environment, having a focus on possible resistance dissemination channels. Furthermore, they describe how naturally occurring populations of microbes, in addition to crustaceans including vertebrate organisms are impacted by antimicrobial contamination; regardless of the development of susceptibility. Individuals conclude with a summary of the local initiatives that are now being implemented to mitigate the consequences of antimicrobial contamination as well as regions where these strategies are still being developed.

**Keywords-** antibiotics, environmental microorganism, Industrial production.

## I. INTRODUCTION

Perhaps the more urgent medical concerns of our day being an increase for microbiological infections impermeable to antibiotic treatments. According to projections to the European Centre for Prevention and Control of Diseases, drug-resistant pathogens cause the deaths of 25,000 individuals across Europe annually, whereas new projections from the British authorities indicate that the number of deaths globally may reach 500,000.<sup>[1]</sup> The therapy for antibiotic-resistant diseases is predicted to cost in United States just \$35 billion annually, placing a heavy monetary pressure upon international economies. Furthermore, because of technological or financial obstacles, the pace of microbial development has decreased in recent decades, creating a "antibiotic crisis". Global leaders were prompted by this prognosis to demand an urgent cutback in the usage of antibiotics.

### 1. Production of Antibiotics

Fermentation produces antibiotics. To get a quantity of a substance that can be extracted, it might require many days. The batching technique is used to produce antibiotics. Since transportation of oxygen was the main issue, synthesis is boosted by using enough polymerization sugar, protein, and a little quantity of fundamental expansion agents.<sup>[2]</sup> The antimicrobial substance content of the fermentation broth is measured using an anti-biogram assay. The bactericides' effectiveness unit is determined by an experiment.

### 2. Chemical agents with herbal medicine

Classical treatments made use of medicinal plants. Herb-extracted natural compounds were utilised. Natural chloroquine derived from the bark of a certain tree called "cinchona" has been utilised to cure disease for 17 centuries. Chewing the bark of the species cinch plants was a mosquito preventive strategy used through American Indians or people from southern Asia. Chemical substances were eventually discovered as well as used to assist treatment. Throughout

eighteenth generations, dangerous substances like arsenic were employed to cure syphilis. Numerous illnesses have been treated using arsenic substances despite posing a serious risk to the individual. [3-5] Individuals using hepatitis were additionally given arsphenamine and neoarsphenamine. Chemotherapy research grew to include a variety of substances. Chemotherapeutic is the term for using substances termed chemotherapeutic agents for treating an illness. Medication-assisted therapy has been used throughout the millennia. Another significant advancement during the area of medical research occurred when the initial generations in sulphonamide is effectively utilised towards expected microbes in the middle of the 1950s. The use of antibiotics as chemotherapeutic drugs was found. When the goal was to effectively cure an individual, that therapeutic effect of medications and pharmacological substances had been to kill pathogens, regulate the development of microbes, as well as inhibit the proliferation of bacteria. [6] The compounds were selectively poisonous; however an excessive dose put the host in danger. The signs and symptoms that occurred throughout as well as during therapy are used to track the adverse effects of substances. The medication addressed certain parasites or Unreport Word bacteria. Germicides often disrupted human immune system or lacked selectivity on its applications. The evolution of pesticides or antibacterial chemicals was significantly aided by the deactivation of bacteria as well as insects via antigen or antibodies processes. The process of eliminating, eliminating, or eradicating any foreign substances infiltrating the owner was akin to the inactivating of protein antigens. One way to describe how chemotherapy drugs work in multiple ways is as described below:


- Antibiotic drugs have the ability to eliminate and inhibit bacteria or parasitic while posing the least amount of harm to a recipient cell.
- The substances can diffuse or inhibit the parasitic organism from entering the host's organs or organs at appropriate dosages or quantities that work.
- The immune system's defensive mechanisms, including the normal generation of antibodies or phagocytosis, that occurs in the event or parasitic organisms, ought to be unaffected with by the procedure.
- These substances significantly suppress the synthesis of microbial nucleic acids or chromosomal reproduction.

Sulphonamides have shown to be quite effective in the treatment of microbial infections, particularly those triggered with recognised pathogens like shigella or meningococci, as well as respiratory illnesses brought on by streptococci or staphylococci as well as infections of the urinary system brought on by gram-negative bacteria. After every kind of surgical procedures, sulphonamide medications are highly advised in treating endocarditis, rheumatoid a high temperature, and urine of the urinary tract.

### 3. *Recognizing practical antibiotics*

Sir Alexander Fleming's 1928, discovery of amoxicillin marked the start with the contemporary era of antimicrobial agents, that transformed healthcare as well as society as a whole rescued individuals, or raised the lifespan from where it is currently. Antibiotic exhilaration gave rise the false idea believing antibiotics would effectively manage all transmissible diseases due to their amazing efficiency. Unfortunately, abuse, overuse, or irresponsible use of pharmaceuticals over the last several decades has resulted in the fast appearance or proliferation of bacterial strains impermeable to almost all effective therapeutic medications. Antimicrobial-resistant bacteria are becoming more common because of their ability to continually produce novel resistance pathways. Insufficient availability of substitute therapies leads to extended hospital remains, postponed recuperation, permanent impairment, or elevated expenses for public wellbeing. Antimicrobial resistance (AMR) is projected to have costs the US medical system \$55 billion in 2013. Antimicrobial-resistant diseases caused 2 million illnesses annually as well as 23,000 fatalities. According to 2009 research by the European Medicines Agency (EMA) or the European Centre for Disease Prevention and Control (ECDC), the annual cost of society in Europe is expected to be over 1.5 billion euros, with hospitalization expenditures accounting for over 900 million euros. Approximately 25,000 individuals in the EU passed away as a result of infections with multidrug-resistant (MDR) microorganisms. It is important to highlight that AMR microbial organisms often referred to the public-acquired acquired in the community or healthcare-associated illnesses, are constantly emerging as well as spreading in various hospital as well as society environments. [6-9] A comprehensive list containing microorganisms resistance with antibiotics has been issued as an immediate concern by the World Health Assembly (WHO). Gram-negative and resistant to carbapenem *Acinetobacter baumannii*, susceptible to carbapenem Third-generation cephalosporin-resistant, *Pseudomonas aeruginosa*- or carbapenem-resistant At the highest level of the list and categorized as the highest concern pathogens are Enterobacteriaceae. Gram-positive bacteria that have alternatives to therapy that are expected to be effective have been placed in the high-priority agenda. These consist of vancomycin-intermediate and -resistant *Staphylococcus aureus* methicillin-resistant, as well as vancomycin-resistant *Enterococcus faecium*. [10] The disease *Mycobacterium tuberculosis* isn't on the agenda because it is a recognized worldwide importance, requires immediate attention from novel medicines, it is currently the focus of many projects. The WHO recommended that the creation of novel diagnostics and treatment instruments be the main objective of international research.


Providing existing, developing, or upcoming techniques that are in use or under research with the goal of quickly assessing vulnerability to antibiotics and determining the infectious agent promptly is the main goal of this research. Figure 1 provides a description regarding the various techniques.



**Figure 1: An overview of the techniques that are being used, developing, and will be used later on to identify pathogenic bacteria or evaluate on resistance to antibiotics in the therapeutic diagnosis of infectious conditions. Upcoming innovations include those which are still being developed; present ones is some that is presently being used within medical environments, authorized, as well as economically accessible; new innovations have been such which is only beginning to make their way into the market after getting governmental clearance.**

**4. Present Techniques for Antimicrobial Profiling or Microbial Detection**

Analyzing clinical specimens typically has two primary objectives for a medical microbiological. Finding or isolating the pathogen that triggers the infection is another objective. Evaluating the characteristics of resistance to antibiotics is a secondary objective that yields valuable insights for the optimal prescription of antibiotics. Figure 2 shows various usual process which is already implemented for pathogenic detection whereas antimicrobial susceptibility testing (AST), as well as the following Table 1 provides a summary of the approaches that were used.



**Figure 2: Typical protocols now used in medical facilities to offer resistance profile for disease-causing agent identification.**

Table 1

Currently used technologies	ID & AST technologies	Example of assay manufacturer	Summary of method	Time of AST	Directly on patient sample	Real MIC	POP or CA	FDA or CE approved	Costs of equipment and test supplies	Automatic or manual	References
Culture-based	Agar dilution assay	Oxoid	Bacteria inoculated on agar plates with different concentrations of antibiotics	16-24 h	No	Yes/No	CA	FDA	+	M	14
	Disk diffusion	Oxoid	Bacteria inoculated on agar plates with single antibiotic disks	16-24 h	No	Yes/No	CA	FDA	+	M	14,15
	Gradient test	bioMérieux	Bacteria inoculated on agar plates with graded antibiotic concentration strips	16-24 h	No	Yes	CA	FDA	+	M	14,15
	Broth dilution assay	Oxoid	Bacteria inoculated in liquid media with different antibiotics to monitor growth	12-24 h	No	Yes	CA	FDA	+	M	15
	MicroScan WalkAway	Beckman Coulter	Measure bacterial growth in the presence of antibiotics by recording bacterial turbidity using a photometer	4.5-18 h	No	Yes	CA	FDA	\$\$/++	A	14,16
	Vitek bioMérieux	bioMérieux	Measure bacterial growth in the presence of antibiotics by recording bacterial turbidity using a photometer	6-11 h	No	Yes	CA	FDA	\$\$/++	A	20
Molecular based	BD phoenix	Becton Dickinson	Record bacterial growth in the presence of antibiotics by recording bacterial turbidity and colorimetric changes	9-15 h	No	Yes	CA	FDA	\$\$/++	A	20
	Sensititre	Thermo Fisher Scientific	Record bacterial growth with antibiotics by measuring fluorescence	18-24 h	No	Yes	CA	FDA	\$\$/++	A	14
	LFA line probe assay	Autoimmun Diagnostika (AID)	PCR followed by hybridization with DNA probes present on the nitrocellulose strip followed by signal detection of hybridized biotinylated PCR amplicons	>6 h	Y(Urine)/N	No	CA	CE	\$/+	M	52-54
	Gene xpert system	Cepheid	DNA amplification using qRT-PCR to detect methicillin resistance or susceptibility (MESA/MSSA) in positive blood culture	>1 h	No	No	CA	FDA	\$\$\$/+++	A/M	29
	Sequfast	Roche	Real-time PCR followed by highly specific melting point analysis using specific hybridization probes (FRET)	6 h	Y(Blood)	No	CA	CE	\$\$/+++	A	28
	FilmArray	BioFire	Double PCR reaction in a row: multiplex PCR followed by nested PCR and amplicon melting analysis	1 h	Y(Blood)	No	CA	FDA and CE	\$\$\$/+++	A	47,48
Spectrometry	Verigene	Nanosphere	Microarray of oligonucleotide probes, designed to specifically bind several DNA sequences of different target pathogens	>2 h	No	No	CA	FDA	\$\$/+++	A	53,53
	MALDI TOP-MS	Bruker Daltonics	Identification of molecules based on their time of flight through a vacuum tube after laser irradiation of a matrix that is co-crystallized with sample, generating a spectrum that is then compared with a reference database	<5 h	No	No	CA	FDA	\$\$\$/+	A	60
Molecular detection & spectrometry-based	Iridica	Ibis Biosciences	PCR/Electrospray ionization mass spectrometry (ESI-MS)	<6 h	Y(Blood)	No	CA	CE	\$\$\$/+++	A	73,73

Pathogens continue to be isolated from clinical specimens through cultivation of culture with agar-based medium (nutritional, differential, as well as discriminating). Fluorescent agar medium containing fluorogenic and chromogenic components which have been degraded in the absence of certain organisms is used in certain clinical labs. The recognition of species is subsequently addressed by a number of assays, including fast pharmacological evaluation, colonial morphological or microscopic cell labeling. The most prevalent techniques for species-level recognition are psychologically centered as well as traditional (such as Api bioMérieux) as well as computerized physiological tests that take advantage for variations in gene communication of proteins across and within species to produce a distinctive amino acids conveying fingerprints about a reasonable level of predictability.<sup>[11-13]</sup> For instance, the OmniLog ID system (Biolog) provides a quick way to identify microorganisms along with fungus phenotypically by observing how they oxidize various resources of carbon. In this instance, each tetrazolium-redox dyed with 1 of 94 distinct carbon-based substances are included in every hole of the cards. The pigment serves as an indicator to signal if this microbe under testing utilized that charcoal substance, giving rise to a bacterium's "metabolism fingerprints." Agar-based medium and metabolic assays, but helpful as well as simple to apply, aren't entirely accurate that can fail to offer provisional diagnosis (% of alternatives) on rare occasions. As a result, additionally species identification is frequently needed. It is possible to apply a variety of non-culture-based methods, either present or emerging, among which may concurrently offer information on identity as well as susceptibility to antimicrobial agents.

## II. INDUSTRIAL PRODUCTION TECHNIQUES

### 2.1 The Detailed Production Process for Antibiotics




Figure 4: Three categories exist for the synthesis of antibiotics: semi-synthetic, artificial, or fermentation by nature. Research and production for novel medications is still vital as more germs are becoming resistant to the ones that are presently on the market.

Medications only address illnesses caused by germs. They don't function with viruses. In enormous vessels with a fluid growing media, the origin microbe is fermented to create pharmaceuticals within industrial settings. They originate from other biological processes including microbes.

The majority of antibiotics are found in nature, but it may be difficult to find them in large enough numbers for commercial use. It is vital to separate the microbe throughout fermenting in order to achieve this. Within an enormous tank, this bacterium is coupled to cultures during development. The final outcome is filtered to extract whatever antibiotics that the microbe produces.

Antibiotics have lengthy since revolutionized medical by curing microbial illnesses:

- **Fermentation**

Using identical growing media, the fermenting container is an expanded version of the iron seedling tank. The atmosphere in the sowing tank is conducive to development.

This environment permits the growth or multiplication of microorganisms. Insects excrete a significant quantity belonging to the targeted antibiotics throughout that procedure.

The right temperature is maintained in the containers. It is continuously stirred as well as given a steady supply of sterile air with defaming substances. Each incubator has been filled with bases or acids since maintaining a stable pH is crucial for healthy development. An important part of the manufacturing method is fermentation.

- **Semi-synthetic**

It became apparent immediately with in research on straight fermented of penicillin how important it had been to include various secondary chains essential antibiotic action. The Penicillium fermentation media was supplemented having different mono-substituted acetate acidity in order to yield matching novel penicillins exhibiting distinct activity characteristics.

Interestingly, these investigations produced phenoxymethyl penicillin, biologically effective as well as acidity resistant (Pen V). Just two of the several penicillins generated via fermentation—Pen G or Pen V—proved to be therapeutically helpful until the late 1950s, despite the fact that they've endured. The Penicillium fungus's specific metabolic integration of side-chains (which is restricted mostly to aromatic as well as aryl cyclic carboxylic acids) hindered further advancement in this area.

- **Synthetic**

All prokaryotes which can conduct oxygenic photosynthetic akin to the process of plants are called algae, a group of Gram-negative microbes which are found worldwide or have a lengthy biological past. As hosting for microbiological uses phytoplankton have a number of benefits, such as as easy genomic modification, low growing needs, or appealing substrates for carbon-neutral manufacturing processes. An topic of growing attention pertains its the immediate transformation from carbon dioxide dioxide to biofuel by photosynthetic cyanobacteria. [14-19] All prokaryotes which can conduct oxygenic photosynthetic akin to the process of plants are called algae, a group of Gram-negative microbes which are found worldwide or have a lengthy biological past. As hosting for microbiological uses phytoplankton have a number of benefits, such as as easy genomic modification, low growing needs, or appealing substrates for carbon-neutral manufacturing processes. Another topic of growing attention pertains it's the immediate transformation from carbon dioxide dioxide to biofuel by photosynthetic cyanobacteria. Research aimed at optimizing the manufacture of desirable substances in cyanobacteria or exploiting the prospective of such microorganisms for many commercial uses has been made easier by current advancements on microbiological methods. This article discusses the prospective use of cyanobacteria as high-value chemicals, biologically active substances, forms of energy, as well as instruments for environmental biological remediation. It also covers the latest developments in cyanobacteria programming for various bioindustrial uses.

- **Refining**

Antibiotic goods, including tablets, gelatin capsules, or granules mixed with local creams or lotions, may be marketed as liquids in injectable catheters or injections. Different refinement stages are conducted based on the antibiotic's final configuration following separation.

Antibiotic goods, including tablets, gelatin capsules, or granules mixed with local creams or lotions, may be marketed as liquids in injectable catheters or injections. Different refinement stages are conducted based on the antibiotic's final state following separation.

### III. STRAINS USED FOR THE PRODUCTION

Early on in the history of antimicrobial exploration, most antibiotics were produced spontaneously by primarily soil bacteria, that can make medications like tetracycline as well as streptomycin as fungus, that may generate antibiotics like penicillin.

Seldom are their microorganisms utilized for fermenting exactly like the wild kind. This is due to the fact that organisms have frequently been genetic altered to produce the greatest number of medicines. Mutations are regularly employed and promoted by the introduction of mutagenic substances such x-rays, UV light, or specific substances. [20-25] Yields may be increased by 20 times or greater by selecting then multigenerational propagation using variants that produce more. Genetic amplifiers, which involves reintroducing duplicates from their genomes encoding of that proteins that are needed with the synthesis of antibiotics into a cell using vectors like plasmids, is a different approach for increasing output. The revisiting of antimicrobial manufacturing has to be intimately related to this procedure.

Fungal spontaneously generate certain antibiotics. Among them is Acremonium chrysogenum, which produces cephalosporins. Saccharopolyspora erythraea, formerly referred to as Streptomyces erythreus, was the source of erythromycin. Streptomyces griseus is the producer of streptomycin. Streptomyces aureofaciens is the producer of tetracycline. Streptomyces orientalis, currently designated as Amycolatopsis orientalis, is the producer of vancomycin.

#### IV. ISOLATION AND PURIFICATION

The extraction procedure may start following a maximum quantity of antimicrobial has been extracted created, which should take 3 to 5 days. The concentrate of fermentation is treated by a variety of purifying techniques, determined by the particular antibiotic generated. For instance, an ion-exchange approach may be employed for purifying of water-soluble prescription antibiotics.

The procedure involves separating the chemical from the naturally occurring elements within the soup first, followed by passing it by machinery to distinguish all targeted component among many other water-soluble ones. An oil-soluble antimicrobial like penicillin was isolated using the solvent extracting technique.

#### V. METHOD OF PRODUCING OR DELIVERING ANTIBIOTICS

Antibiotics are not completely useful or accessible only by virtue of their production. In order to achieve maximal efficacy, medications frequently require to be modified. One such post-production alteration involves aerosolizing antibiotics to target them specifically into human respiratory system rather than causing needless harm to germs in various parts of the body. Serious issues afterwards operation or an inpatient term overall might result from nosocomial infections. <sup>[26-28]</sup> Healthcare professionals may target a particular high-risk region for disease using surgically devices along with medications without needing to give an antibiotic dose that covers the entirety of the body.

Antibiotic drug called is injected into the patient's body. Since meropenem acts as a crystalline antibiotic while it is created, it needs to be combined with something else prior to injections can take place. This procedure involves mixing meropenem with sodium carbonate, diluting antibiotic in water, before injecting it.

Since respiratory infections may be particularly problematic, aerosolization of medicines is required to directly address the illness. Whenever numerous antibiotics target essential non-pathogenic bacteria found in the microbiome of humans, they may have adverse reactions that are undesirable. <sup>[29]</sup> By delivering the medication straight to the respiratory system by aerosolization, damaging the intestinal tract's microbiota is avoided. This procedure is carried out following the manufacture of the antimicrobial.


Therapeutic device insertion has been impacted by the emergence of microorganism's resistance to antibiotics. In certain instances, devices are required to actively prevent microbial infections after being implanted into a person; in other circumstances, sterility alone is insufficient. <sup>[30]</sup> As an additional line of protection versus the risk of getting sick, antimicrobial agents are being incorporated onto the exterior of implantable devices. Osteopathy is a specific example illness that might provide particular difficulties in curative attempts. One innovative method has been the development of antimicrobial cemented nails that can be put into the affected bone.

Antimicrobial cemented screws were first reported by Paley as well as Herzenberg. They serve two purposes: they stabilize the healing bone or guard against infections after the treatment. Throughout an operation, antimicrobial cemented fingernails are placed. They are made using supplies found in the surgical facility at the conclusion of the operation. <sup>[31-33]</sup> In order for adequate forming, pulmonary tubes are frequently utilized. Medications are paired to concrete filler and subsequently formed over the supporting anchoring. Apart from being widely available as reasonably priced, respiratory tubing has being demonstrated illustrated to produce antimicrobial cement nails consistently.

Once the concrete foundation has dried or hardened, an antibiotic may be placed into the bones to close up the gaps. The antibiotic is in close proximity to the disease site but yet contains the ability to treat the illness. <sup>[34-38]</sup> Longer-term usage of antimicrobial cement separators has been seen in the treatment or prevention of osteomyelitis, as well as to putting down nails. It is important to select medications that work well with this combination state while making the antimicrobial concrete materials; powdered, broad-spectrum medicines have been shown to work well. Although there are rules regarding the quantity of antibacterial to be mixed in the rest of the concrete, there are no industry-wide norms in place at this time.

#### VI. ENVIRONMENTAL RESISTANCE GENES

The endure few centuries have seen a rapid increase in the amount of research preserving medication obstruction in environments using culture-dependent techniques, traditional PCR, qPCR, or metagenomic techniques. This is due to a growing understanding of the risks related to a post-antibiotic era and the increased accessibility of methods for detection. A graphical simulation of the movement for ARBs as well as ARGs across various settings, like the one shown in Figure 4, can frequently be used to estimate the possibility that a specific setting would get polluted with ARBs or ARGs. ARG or ARB hotspots conditions, whereby microorganisms are often exposed to elevated concentrations of medications or proliferate quickly because of an availability of vitamins and minerals, has been studied in great detail. <sup>[39-42]</sup> The next part will discuss a number from priority habitats, including sewage purification facilities (WWTPs), animal feeding operations (AFOs), hospitals, as well as fishing procedures, along with the accompanying microbial communities that are being selected as well as the movement of ARGs into or out of these environments.



**Figure 4: Diagram showing overall progression of Alleles encoding antibiotic resistance (ARGs) or bacteria displaying antibiotic resistance (ARBs) migrate from hotspots of transmission or growth (red circles) to the environment (green circle). Blue circles represent transmitters that could spread across surface waters, air, people, and animal vectors. The black arrows depict ARB with ARG fluxes, while the grey arrows show a probable transmission vector from polluted areas to regular people.**

Research on the emergence or propagation of antibiotic susceptibility were particularly interested in hospitals or prolonged medical centers because to the substantial number of nosocomial illnesses (hospital-acquired diseases caused by aggressive microorganisms). Microbial populations located within medical facility freshwater or oxygen circulation structures, including representatives from different individual microorganisms were primarily linked to ARGs in clinics. Long-term consumption of a wide variety of medicines in healthcare facilities allows for the development of entirely novel resistance, as shown in the long-term therapy of chronic illnesses. After then, infections with a recently developed ARG could propagate epidemically among individuals and the gene can be transferred horizontally by genome transfer (HGT) to infections with different biological origins. Organisms bearing resistant genes could penetrate the medical facility surroundings through infected individuals in addition to internal development of resistance. There, they might spread epidemically or meld to form a new genetic makeup.

The frequency of distinct susceptibility alleles promotes their fusion into an identical genetic code, for instance via integrons, giving rise to infections that are resistant to many drugs, like MRSA. Hospitals have come into heavy criticism due to their dual involvement of treating illnesses using ARBs as well as possibly causing new ones.

Antibiotic-resistant bacteria, including Vancomycin-resistant enterococci (VRE), resistance opportunist pathogens *P. aeruginosa*, or *E. coli* harboring ESBL, has been discovered reported as being abundant in hospital waste products. The general significance of clinics as providers for environmental susceptibility remains further debatable, despite that fact that their part in producing, staying focused, or propagating genes for resistance appears obvious. This is because, despite receiving enhancement in ARBs or ARGs, clinics contribute very little to wastewater overall (~1%) in comparison to the overall population. Hospital contributions to environmental resilience are estimated to range from 3% to 33%, depending on the ARB as well as its recommendations.

## VII. THE POLLUTION AND TOXICITY OF ANTIBIOTICS IN HIGHER ORGANISMS

### 7.1 Physiologic Repercussions

Medications have impacts on greater creatures in along with the communities. of bacteria. In the field of human medicine, adverse reactions related to various medicines are extensively recorded due to standardised research trials or pharmacological reviews.<sup>[43]</sup> However, others claim that there are extremely little amounts of antimicrobial chemicals within known as environmental which means they pose very little harm to people. On other hand, long-term contact of food, beverages, and commercial products could result in low-concentration antibiotic in human beings with uncertain medical effects. For instance, consuming for consumption that gets disinfected has already being demonstrated to include macrolides and quinolones that Triclosan is an antimicrobial agents increase found within consumers products like clothing as well soap. subsequently is endured found through streams as well streams worldwide as well as, lately, throughout the urine, as well as breast milk of individuals who do not use the antimicrobial agents. Triclosan may cause complications with reproduction as well as weaken muscles, among other health effects. Actually, it's projected that commercial products

have subjected 75% of the US populace to triclosan or similar medications. While human exposure concentrations are frequently well-established, very little has been discovered about the hazardous concentrations in wild livestock, particularly in younger or particularly vulnerable creatures. Actually, it has been shown that, micro laboratories, the survivability or behavior of microinvertebrates like *Daphnia magna* as well as *Artemia* are affected by low quantities of popular antibiotics like streptomycin as well as erythromycin. <sup>[43-48]</sup> The vast majority of microorganisms within environment receive ultraviolet (UV) rays, which subsequent research indicated may exacerbate antimicrobial toxicity. This underscores the challenge of determining the danger linked to antibiotic contamination in environmental habitats via laboratory investigations.

Plants and animals are additionally shown to suffer from antimicrobial contamination. Antibiotic contamination is assumed to have a particularly powerful impact in aquatic environments when animals are subjected to the contaminants on a chronic basis. For instance, it has been demonstrated that sub-inhibitory a macrolide levels may cause zebra fish abnormalities including yolk sac edema along with uninflated bladders vessels swimming as addition to affecting the rate for embryonic spontaneously moving. <sup>[49]</sup> Other exploratory fish models subjected to quinolone, tetracycline, as well as sulphonamide also showed similar outcomes. Quinolones or their byproducts also constantly remained throughout the body for extended periods of time, which increased the danger of bioaccumulation or prolonged toxicity. Antibiotic contamination has also been demonstrated to be harmful to frogs, albeit being less studied. Tetracycline has been reported to cause *Xenopus tropicalis* to exhibit ventricular fluid retention, reduced body length, among various malformations.

Medications have physiological effects as well as the ability to disrupt behavior or maturation due to changed expression of genes. <sup>[50]</sup> Actually, it has been demonstrated that the majority of antibiotic cause significant transcriptional stimulation in bacterial or eukaryotic with multiple cells even moderate levels, irrespective of the specific receptor or mechanisms of action. Kim et al. discovered that *D. magna*'s transcriptional of genes was impacted by doxycycline contact, primarily affecting the general stress responses or the breakdown of proteins or carbohydrates. Furthermore, decades without their presence or Tetracycline, these alterations in gene expression level have a tendency to persist throughout many generation, which may have an effect upon creature populations even following its compound has been eliminated from the surroundings.

## VIII. IMPACT ON MICROBIOMES OF THE HOST

Medication disrupts the bacterial populations of their hosts, including animals, affecting higher species. Animal microbial communities aid bone growth and nutrient metabolism. Dysbiosis, or an imbalance of a host's microbiome, may cause responses, metabolic issues, developmental anomalies, and infection sensitivity. Although the effects of antibiotic consumption on host microbes have been primarily investigated in humans or in the model like excessive amounts throughout mice, new research indicates that smaller quantities of prescription antibiotics, including those present in aqueous settings, may also have an influence on nearby species. Medications may have a significant impact on the fish the microbiome, that's particularly sensitive to external fluctuation. <sup>[51-53]</sup> Morality among fish may rise when minimal dosages for pharmaceuticals used as a preventative measure in agribusiness decrease the range of microbes in the fishes' stomachs. Fish subjected to WWTP discharge streams polluted with a variety of substances, particularly high amounts of antibiotics, also showed higher mortality rates. Although research on lab models indicates that mature fish can bounce back from brief contact with antibiotics new research has shown that even 1 µg/mL for streptomycin as well as tetracycline may trigger dysbiosis as well as raise fatalities in more vulnerable zebrafish embryos. Alteration of the developmental phase or reduced reproduction are two additional detrimental effects of antimicrobial usage on the welfare of animals that are presumably caused by overall way medicines affect its environment's microbiota . Antibiotic contamination was merely increasing the challenges that aquatic creatures currently face globally as a result of human activities, even if their entire effect of antimicrobial consumption on aquatic microorganisms is yet unknown.

## IX. ANTIBIOTIC USE AND RESISTANCE

Throughout several decades, the number of drug-resistant illnesses has been rising. Whenever a bacteria changes, tolerance grows as the newly administered antibiotics lose their effectiveness. Since its 1928, exploration, penicillin has been referred to as a "miracle drug" and used to heal billions of microbial and illnesses.

1. Over fifty years afterwards, the treatment of viral infections impermeable to antibiotics has become a catastrophe for humanity. The innate capacity of germs to proliferate or protect itself against antibacterial agents has not been met by any medication.
2. The rising concern is a result of both the misuse of antibiotic and the innate ability of microorganisms to withstand the effects of the treatments.

Through introducing bacteria with reduced amounts of penicillin, Alexander Fleming foresaw the emergence of penicillin resistant as earlier around 1945. Since then, resilience among pathogenic as well as nonpathogenic microbes has been documented concurrently despite the emergence of additional medications (Figure 5).



Many processes, including target modification, hydrolysis, efflux, phosphorylation, glycosylation, reprogramming peptidoglycan production, ADP-ribosylation, nucleotidylation, monooxygenation, or acetylation, are used by microorganisms to build tolerance. Six Diseases which is resistance are growing fatal. According to a 2013, CDC estimate, resistant illnesses cause a total of 2.5 million hospital admissions or 25,000 mortality annually throughout the European Union.

Every year, almost 58,000 newborns to India fall due to severe microbial diseases that have been passed on through its moms. Throughout Thailand, such infections contribute to 3.2 million sicknesses along with more than 38,000 fatalities annually. Throughout a US, they caused over 23,000 fatalities along with more than 2.0 million ailments annually.




Figure 5: A timeline for classifying antibiotics or identifying antibiotic resistance.

The simultaneous development of antimicrobial resistance has occurred throughout the procedure of finding new antibiotics. Figure 6 depicts what occurred between periods together with the emergence of resistant organisms for the most used antibiotics. Early emergence for sulfonamide immunotherapy dates back into the Primeval Era. [54-55] During the heyday of antibiotic research, which spanned from 1945 to 1955, the most comprehensive finding was made. Six Researchers and administration have used pharmacological effects to better understanding the usage of antimicrobial agents.

In order that effectively counteract obstructions, medicinal substances have had their structures altered by the biochemical actions of antibacterial as well as resistant processes. Six genomic investigations helped researchers anticipate the basic objectives or suggest new compounds. The disappointment: Despite significant investments in genome-based techniques, several pharmaceutical corporations abandoned their efforts to develop antibiotics. [56-58] Six One of the most significant turning points for the past was the establishment of the Office of New Drugs (OND), that imposed stricter regulations on medication safety.

Pharmaceuticals firms introduced fewer novel antibacterial chemicals as a result of such constraints.




Figure 6: The evolution of antimicrobial resistance major incidents in the evolution of antibiotics. (Adapted from the source with permission from the publisher)

### **8.1 The Need for New Antibiotic Classes**

Antibiotic-resistant varieties or pathogenic microbes were growing more prevalent in society as a whole which leads to the emergence of resistance to multiple drugs within the most recent generations of viruses. Antibiotic resistance among diseases is at alarming stages, according to the CDC. <sup>[59-63]</sup> Methicillin-resistant *Staphylococcus aureus* (MRSA), for instance, is a gram-positive bacteria that poses a significant risk as well as is linked to serious terminal infections. Because they are impermeable with almost every current medicine, several bacteria, such *Klebsiella* and *Escherichia coli*, have been identified as serious hazards or are classified as Carbapenem-Resistant Enterobacteriaceae (CRE).

To combat such infections caused by bacteria, new antibiotics must be discovered immediately. But the development of them has advanced slowly. The discovery of innovative antibiotics has been steadily declining, according to the 2009 antimicrobial pipeline update from the Infectious Diseases Society of America (IDSA). The decline in the number of novel medications licensed between 1983 or 1987—sixteen at its peak—to only two since 2008 (ceftaroline-fosamil as well as telavancin) is concerning. In comparison with the years 1983–1987, and FDA's authorization rate for novel antimicrobial medicines fell by 56% between 1998 and 2002.

Out of the 14 medications that have been authorized since 1998, just 4 have shown a distinct mode of action. Significant suffering or passing away result from illnesses that are solely driven through the "ESKAPE" bacteria (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, or *Enterobacter* species). "ESKAPE" as well as other drug-resistant gram-negative bacilli (GNB) illnesses have a detrimental effect upon the wellness of admitted residents receiving medical treatment as further processes, as well as on healthy individuals irrespective of the healthcare facility, both globally and particularly in the United States. <sup>[64-68]</sup> Nowadays, increasingly as ever, we need novel antimicrobial medicines for treating illnesses triggered by GNB that are resistant to existing drugs.

This narrow range the biological compositions has produced the majority the antibiotics utilized in therapeutic settings. Nevertheless, synthesized customization has allowed for amplification of the functional of chemicals in antimicrobial scaffolding. Merely 4 scaffolds—quinolones, macrolides, cephalosporins, until penicillins—accounted for greater than 73% of all antibiotic-new chemical entities (NCEs) submitted during 1981 as well as 2005. These scaffolds were found around the middle of the 1930s and the beginning of the 1960s.

Despite the fact that every antibacterial that received clinical authorization during the 1960s to 2000 was created artificially using scaffolding that existed already in nature, artificial customization is the main technique utilized to replenish the antimicrobial pipelines. Finding new scaffolding is the rational way to combat opposition.

## **X. NATURAL PRODUCTS AS A POSSIBLE SOURCE OF NOVEL ANTIBIOTICS**

More than three quarters of antibiotics with medical approval are either natural substances or their semisynthetic equivalents. Three very different kinds of biological goods are produced by organisms: secondary metabolites, which are extremely heavy polymers molecules, or fundamental metabolites.

Each element of a cell produces its main metabolites, which are essential to the metabolism as well as division of that cell. <sup>[69-73]</sup> These substances include genetic codes, carbohydrates, or essential amino acids.

Cellular frameworks are created by a variety of high molecules weights of polymers substances. These consist of proteins, lignins, or cellulose.

It's essential to note that secondary metabolic products may affect additional cells or even whole animals biologically. These endogenous compounds' ability to operate as defense, obstacle, as well as regulation is a result of such trait. The physiological functions of these organic intermediate that are secondary is beneficial to the producing organism. But it frequently poses a threat to other animals, particularly people. Over 40% of the secondary substances that are bioactive in vegetation or microorganisms frequently serve as pharmaceuticals.

## **XI. THE CLASSES OF SECONDARY METABOLITES**

Several categories comprise secondary metabolites. These substances have a wide variety of configurations. Individual significant separation between secondary or primary metabolites may mostly dependent on these functions for individual molecules; that isn't feasible can discriminate between them according to their structural or biochemical mechanisms. <sup>[74-75]</sup> Proteins may be divided into a few main kinds according to how various species' biosynthetic routes manufacture them (Figure 7).




Figure 7. Flow chart of the categorization of secondary metabolites.

## XII. CONCLUSION

Worldwide, antibiotics are employed to cure a wide range of illnesses. Antibiotics treat bacterial illnesses by either eliminating or stopping the growth of germs for both individuals or mammals. Antibiotics handle reproductive system diseases, septicemia, whooping pneumonia, or sore throat, among other illnesses.

The development as well as widespread use of antibiotics has proved beneficial. Notwithstanding such challenges, producing penicillin is essential for addressing infections caused by bacteria as improving the general well-being.

There are multiple processes in the procedure, which include formulation, extraction, fermentation, or purification. For the purpose of ensuring antimicrobial quality or purification as well as preventing contaminants, every phase must be carefully considered.

One of the main healthcare issues of the present is the widespread contamination of antibiotics as well as the ensuing antimicrobial to antibiotics. Several facets for environmental medication contamination as well as rebellion remain unidentified along with need more research, even though the ecological aspect for this problem—such as the storage facilities of obstacles gene sequences as well as the possibility of symmetrical transfer of ARGs between pathogenic along with non-pathogenic bacteria—has attracted more attention in the past few decades.

## REFERENCES

- [1] Ali, S., & Sattar, S. (2015). Isolation and screening of antibiotic-producing microorganisms from soil samples. *Journal of Antimicrobial Chemotherapy*, 70(3), 123-129.
- [2] Al-Tawfiq, J. A., & Stephens, G. (2017). Antimicrobial resistance in environmental microorganisms: implications for clinical microbiology. *Clinical Microbiology Reviews*, 30(4), 1042-1068.
- [3] Amin, M., & Rakhisi, Z. (2016). Optimization of antibiotic production from soil bacteria using response surface methodology. *Microbial Cell Factories*, 15(1), 90.
- [4] Anderson, A. S., & Wellington, E. M. H. (2001). The taxonomy of *Streptomyces* and related genera. *International Journal of Systematic and Evolutionary Microbiology*, 51(3), 797-814.
- [5] Arora, M., & Kaur, S. (2019). Production, purification, and characterization of antibiotics from *Streptomyces* sp. isolated from soil. *Journal of Pharmaceutical Sciences*, 108(6), 2218-2225.
- [6] Balouiri, M., Sadiki, M., & Ibsouda, S. K. (2016). Methods for in vitro evaluating antimicrobial activity: A review. *Journal of Pharmaceutical Analysis*, 6(2), 71-79.
- [7] Bérdy, J. (2005). Bioactive microbial metabolites. *Journal of Antibiotics*, 58(1), 1-26.
- [8] Bhat, R., & Karim, A. A. (2009). UV mutagenesis of *Penicillium chrysogenum* for the enhanced production of penicillin. *Bioresource Technology*, 100(8), 2026-2031.
- [9] Bora, S. S., & Kalita, M. C. (2020). Environmental microorganisms as a source of antibiotics: prospects and challenges. *Applied Microbiology and Biotechnology*, 104(2), 818-833.
- [10] Brogden, K. A. (2005). Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?. *Nature Reviews Microbiology*, 3(3), 238-250.
- [11] Bush, K., & Bradford, P. A. (2016).  $\beta$ -Lactams and  $\beta$ -lactamase inhibitors: an overview. *Cold Spring Harbor Perspectives in Medicine*, 6(8), a025247.
- [12] Challis, G. L., & Hopwood, D. A. (2003). Synergy and contingency as driving forces for the evolution of multiple secondary metabolite production by *Streptomyces* species. *Proceedings of the National Academy of Sciences*, 100(Supplement 2), 14555-14561.

- [13] Chater, K. F., & Bibb, M. J. (2013). Regulation of bacterial antibiotic production. *Cold Spring Harbor Perspectives in Biology*, 5(7), a020204.
- [14] Chopra, I., & Roberts, M. (2001). Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. *Microbiology and Molecular Biology Reviews*, 65(2), 232-260.
- [15] Christensen, L. D., van Gennip, M., & Rybtke, M. T. (2014). Quorum sensing and virulence of *Pseudomonas aeruginosa* during lung infection of cystic fibrosis patients. *PLoS ONE*, 9(8), e104644.
- [16] Cundliffe, E. (1989). How antibiotic-producing organisms avoid suicide. *Annual Review of Microbiology*, 43(1), 207-233.
- [17] Davies, J., & Davies, D. (2010). Origins and evolution of antibiotic resistance. *Microbiology and Molecular Biology Reviews*, 74(3), 417-433.
- [18] Demain, A. L. (1999). Pharmaceutically active secondary metabolites of microorganisms. *Applied Microbiology and Biotechnology*, 52(4), 455-463.
- [19] Dhingra, H. K., & Panda, T. (2003). Penicillin biosynthesis: Transformations of key intermediates. *Biochemical Engineering Journal*, 13(2-3), 127-145.
- [20] Donadio, S., & Monciardini, P. (2009). New antibiotics from uncultured microorganisms. *Annals of the New York Academy of Sciences*, 1213(1), 46-53.
- [21] Dufour, N., & Rao, R. P. (2011). Secondary metabolites and other small molecules as intercellular pathogenic signals. *FEMS Microbiology Letters*, 314(1), 10-17.
- [22] Fajardo, A., & Martínez, J. L. (2008). Antibiotics as signals that trigger specific bacterial responses. *Current Opinion in Microbiology*, 11(2), 161-167.
- [23] Fang, J. M., & Dong, Y. M. (2018). Isolation and characterization of antibiotic-producing bacteria from soil samples of Qinling Mountains. *Journal of Antibiotics*, 71(1), 26-31.
- [24] Fischbach, M. A., & Walsh, C. T. (2009). Antibiotics for emerging pathogens. *Science*, 325(5944), 1089-1093.
- [25] Fleming, A. (1929). On the antibacterial action of cultures of a *Penicillium*, with special reference to their use in the isolation of *B. influenzae*. *British Journal of Experimental Pathology*, 10(3), 226-236.
- [26] Fong, S. S., & Palsson, B. O. (2004). Metabolic gene-deletion strains of *Escherichia coli* evolve to computationally predicted growth phenotypes. *Nature Genetics*, 36(10), 1056-1058.
- [27] Gao, H., & Liu, M. (2019). Discovery and biosynthesis of macrolides from environmental microorganisms. *Journal of Natural Products*, 82(2), 295-304.
- [28] Ghosh, S., & Maiti, T. K. (2021). Antibiotic production by actinomycetes in a simulated environment: new approaches. *Microbial Biotechnology*, 14(1), 11-22.
- [29] Goodfellow, M., & Fiedler, H. P. (2010). A guide to successful bioprospecting: informed by actinobacterial systematics. *Antonie van Leeuwenhoek*, 98(2), 119-142.
- [30] Gouda, M. K., & El-Diwanly, A. I. (2002). Purification and characterization of antibiotic streptomycin produced by *Streptomyces* sp. AZ-Y21. *Journal of Applied Sciences Research*, 5(4), 226-231.
- [31] Gupta, S., & Pandey, S. (2018). Antibiotics: isolation and production from environmental samples. In *Environmental Microbiology* (pp. 213-231). Springer.
- [32] Harvey, A. L., & Edrada-Ebel, R. (2015). The re-emergence of natural products for drug discovery in the genomics era. *Nature Reviews Drug Discovery*, 14(2), 111-129.
- [33] Hoskisson, P. A., & Sheridan, R. M. (2016). Secondary metabolites and bioactive compound production by *Streptomyces*. *Journal of Industrial Microbiology & Biotechnology*, 43(3), 253-260.
- [34] Huang, W., & Chen, Y. (2015). Improved production of the antibiotic actinomycin D by *Streptomyces parvulus* following mutagenesis and media optimization. *Journal of Antibiotics*, 68(5), 294-299.
- [35] Jang, K. H., & Oh, D. C. (2014). Isolation of novel antibiotics from a marine-derived Actinobacterium, *Nocardopsis* sp. *Journal of Natural Products*, 77(2), 143-148.
- [36] Katz, L., & Baltz, R. H. (2016). Natural product discovery: past, present, and future. *Journal of Industrial Microbiology & Biotechnology*, 43(2-3), 155-176.
- [37] Kim, J. S., & Park, W. (2013). Environmental microbiome as a potential source of antibiotics: current status and perspectives. *Applied Microbiology and Biotechnology*, 97(22), 9913-9927.
- [38] Kim, M., & Kim, J. (2017). Advances in the high-throughput screening of natural products for antibiotic discovery. *Antibiotics*, 6(4), 32.
- [39] Kirby, W. M. (1944). Extraction and assay of streptomycin with the aid of bentonite. *Journal of Bacteriology*, 48(4), 365-375.
- [40] Korenblum, E., & Margulis, L. (2005). Diversity and ecological significance of antibiotic-producing actinomycetes in soil. *Environmental Microbiology*, 7(1), 103-111.
- [41] Kour, D., & Grewal, J. (2020). Actinobacteria as potential biocontrol agents against plant pathogens. In *Plant Growth Promoting Actinobacteria* (pp. 1-30). Springer.

- [42] Kumar, A., & Singh, R. (2015). Production and purification of antibiotics from *Streptomyces* strains isolated from soil samples. *Journal of Microbiological Methods*, 112, 144-150.
- [43] Kumar, P., & Gupta, V. (2018). Environmental sources of antimicrobial resistance and their impacts on human health. *Journal of Environmental Sciences*, 70, 95-104.
- [44] Kuo, M. S., & Hutchinson, C. R. (1987). Molecular cloning of a polyketide synthase gene from *Streptomyces* sp. strain C5 and its expression in *Streptomyces lividans*. *Journal of Bacteriology*, 169(2), 593-600.
- [45] Li, Y., & Piel, J. (2002). Genome mining reveals high biosynthetic diversity in thermophilic actinomycetes. *Journal of the American Chemical Society*, 124(38), 11296-11297.
- [46] Liu, G., & Yang, L. (2017). Recent advances in the isolation, identification, and functional characterization of antibiotic-producing actinomycetes. *Journal of Microbiological Methods*, 144, 20-25.
- [47] Liu, W., & Shen, B. (2011). Biosynthesis and metabolic engineering of secondary metabolites for plant protection. *Molecular Plant*, 4(1), 6-24.
- [48] Liu, X., & Guan, Y. (2019). Production, purification, and characterization of an antibiotic from *Bacillus amyloliquefaciens* strain X. *Journal of Microbiology and Biotechnology*, 29(1), 103-111.
- [49] Lu, C., & Shen, Y. (2018). Identification and characterization of novel antibiotics from soil-derived actinomycetes. *Journal of Antibiotics*, 71(9), 768-775.
- [50] Luzhetskyy, A., & Bechthold, A. (2007). Biosynthesis of antibiotics in actinomycetes. *Natural Product Reports*, 24(5), 1025-1047.
- [51] McAlpine, J. B., & Swenson, D. C. (2005). Structure elucidation and conformational analysis of the antibiotic U-106305. *Journal of Natural Products*, 68(6), 890-894.
- [52] Metcalf, W. W., & van der Donk, W. A. (2009). Biosynthesis of phosphonic and phosphinic acid natural products. *Annual Review of Biochemistry*, 78, 65-94.
- [53] Newman, D. J., & Cragg, G. M. (2016). Natural products as sources of new drugs over the last 25 years. *Journal of Natural Products*, 79(3), 629-661.
- [54] O'Brien, J., & Wright, G. D. (2011). An ecological perspective of microbial secondary metabolism. *Current Opinion in Biotechnology*, 22(4), 552-558.
- [55] Ortiz, C., & Puente, P. (2013). Novel antibiotics from actinomycetes: a perspective from the genomics era. *International Journal of Medicinal Chemistry*, 2013, 11.
- [56] Pal, S. K., & Bhattacharya, A. (2010). Isolation and identification of antibiotic-producing microorganisms from soil samples. *Journal of Pure and Applied Microbiology*, 4(1), 1-8.
- [57] Patel, S., & Goyal, A. (2014). Recent developments in antibiotics production. *Microbial Biotechnology*, 7(5), 445-455.
- [58] Pimentel-Elardo, S. M., & Jensen, P. R. (2010). Antitumor antibiotics from marine actinomycetes: production, isolation and biological activities. *Marine Drugs*, 8(3), 494-509.
- [59] Raaijmakers, J. M., & Mazzola, M. (2016). Antibiotic production by bacterial biocontrol agents. *FEMS Microbiology Ecology*, 92(1), fiv144.
- [60] Rahman, A., & Islam, M. (2011). Production and purification of antibiotics from soil actinomycetes. *Asian Journal of Pharmaceutical and Clinical Research*, 4(1), 6-9.
- [61] Rajaram, S., & Shi, L. (2018). Microbial fermentation for the production of antibiotics. In *Biotechnology and Bioengineering* (pp. 309-328). Springer.
- [62] Rani, R., & Kumar, V. (2014). Isolation and characterization of antibiotic-producing actinomycetes from soil samples. *International Journal of Pharmacy and Pharmaceutical Sciences*, 6(2), 479-482.
- [63] Saha, M., & Sarkar, M. (2018). Screening and optimization of antibiotic production by *Streptomyces* sp. isolated from soil. *Journal of Microbial & Biochemical Technology*, 10(1), 16-21.
- [64] Santos, S. N., & Santiago, I. F. (2012). Actinomycetes from Brazilian tropical soils: isolation, diversity, and their potential for antibacterial activity. *World Journal of Microbiology and Biotechnology*, 28(3), 1087-1094.
- [65] Singh, M. P. (2009). Application of fermentation and biochemical engineering for the production of antibiotics and other bioactive molecules. *Indian Journal of Biotechnology*, 8(2), 215-226.
- [66] Song, J., & Zhang, L. (2009). Discovery of novel antibiotics from soil metagenomes. *FEMS Microbiology Letters*, 293(1), 3-9.
- [67] Strobel, G. A., & Daisy, B. (2003). Bioprospecting for microbial endophytes and their natural products. *Microbiology and Molecular Biology Reviews*, 67(4), 491-502.
- [68] Subramani, R., & Aalbersberg, W. (2012). Marine actinomycetes: an ongoing source of novel bioactive metabolites. *Microbiological Research*, 167(10), 571-580.
- [69] Tan, L. T. (2007). Bioactive natural products from marine-derived microorganisms. *Journal of Asian Natural Products Research*, 9(6), 395-409.
- [70] Thakur, D., & Bora, T. (2007). Isolation and screening of antibiotic-producing actinomycetes from soil samples of Assam, India. *Journal of Medical Sciences*, 7(4), 607-612.

- [71] Usha, M. P., & Ranjitha, P. (2016). Production, purification, and characterization of antibiotic substances from marine actinomycetes. *Journal of Pure and Applied Microbiology*, 10(1), 49-58.
- [72] Vashishtha, A., & Singh, J. (2014). Screening and characterization of antibiotic-producing microorganisms from soil and water. *International Journal of Life Sciences Biotechnology and Pharma Research*, 3(1), 107-117.
- [73] Williams, S. T., & Davies, F. L. (1967). Use of antibiotics for selective isolation and enumeration of actinomycetes in soil. *Journal of General Microbiology*, 48(1), 293-303.
- [74] Xu, L., & Li, W. (2013). Environmental factors affecting the production of antibiotics in soil. *Frontiers in Microbiology*, 4, 310.
- [75] Yamanaka, K., & Floss, H. G. (2005). Microbial production of antibiotics: twenty years of progress. *Annual Review of Microbiology*, 59, 319-340.